A phase 1 study of MORAb-004 in patients with solid tumor

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222023

Enrollment

Registered

2013-02-19

Start date

2013-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

investigational material(s) Generic name etc : MORAb-004 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent, 2. Japanese male and female subjects aged 20 or older at informed consent, 3. Have malignant solid tumor, without intracranial involvement or metastasis diagnosed by standard pathology criteria that are resistant to standard chemotherapy, 4. Performance status (PS) is 0-1 by Eastern Cooperative Oncology Group, 5. With no carry-over effect and no adverse drug reaction of prior treatment which may affect the safety evaluation of MORAb-004 (except for Grade 1 or 2 neuropathy and alopecia), 6. Survival expectation is 12 years or longer after starting MORAb-004 administration

Exclusion criteria

Exclusion criteria: 1. Have clinically, significant cardiovascular disease, 2. Scheduled for laparotomic surgery due to trauma or other reasons for during the study, 3. Have clinically significant hemorrhagic event or history, or event with high risk of hemorrhage, 4. Receiving chronic systemic anticoagulation, 5. Have evidence of other active invasive malignancy, 6. Females who are lactating or pregnant at Screenint or Baseline

Design outcomes

Primary

Measure	Time frame
Tolerability and safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026